Previous studies supported abrine, Benzo(A) Pyrene, bisphenol A, Soman, Sunitinib, Tetrachloroethylene, and Valproic Acid can target CCDC134 in vitro and is expected to make new progress in the treatment of breast cancer. This evidence concerns the gene CCDC134 and breast carcinoma.